Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drug Use Investigation of Regorafenib/STIVARGA for Gastrointestinal Stromal Tumor Progressed After Cancer Chemotherapy

Next Previous
Trial Profile

Drug Use Investigation of Regorafenib/STIVARGA for Gastrointestinal Stromal Tumor Progressed After Cancer Chemotherapy

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Adverse reactions; Registrational
  • Sponsors Bayer

    • Most Recent Events

    • 23 Aug 2019 Status changed from recruiting to active, no longer recruiting.
    • 23 Nov 2018 Planned primary completion date changed from 30 Jun 2021 to 30 Nov 2020.
    • 28 Apr 2018 Planned End Date changed from 25 Jun 2021 to 30 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top